JavaScript NENÍ povolen !

Prosím povolte JavaScript.

* Zobrazit nápovědu

Reset

Pracoviště: Department of Microbiology and Immunology Dalho...

1 záznamů v PubMed Filtry

Článek

Trial Watch: Oncolytic viro-immunotherapy of hematologic and solid tumors

Pol, Jonathan G
Autor Pol, Jonathan G Gustave Roussy Comprehensive Cancer Institute, Villejuif, France INSERM, Paris, France Equipe 11 labellisée par la Ligue Nationale contre le Cancer, Centre de Recherche des Cordeliers, Paris, France Université Paris Descartes/Paris V, Sorbonne Paris Cité, Paris, France Université Pierre et Marie Curie/Paris VI, Paris, France
Lévesque, Sarah
Autor Lévesque, Sarah Gustave Roussy Comprehensive Cancer Institute, Villejuif, France INSERM, Paris, France Equipe 11 labellisée par la Ligue Nationale contre le Cancer, Centre de Recherche des Cordeliers, Paris, France Université Paris Descartes/Paris V, Sorbonne Paris Cité, Paris, France Université Pierre et Marie Curie/Paris VI, Paris, France
Workenhe, Samuel T
Autor Workenhe, Samuel T McMaster Immunology Research Centre, McMaster University, Hamilton, ON, Canada Institute for Infectious Disease Research, McMaster University, Hamilton, ON, Canada Department of Pathology and Molecular Medicine, McMaster University, Hamilton, ON, Canada
Gujar, Shashi
Autor Gujar, Shashi Department of Pathology, Dalhousie University, Halifax, NS, Canada Department of Microbiology and Immunology, Dalhousie University, NS, Canada Department of Biology, Dalhousie University, NS, Canada Centre for Innovative and Collaborative Health Sciences Research, Quality and System Performance, IWK Health Centre, Halifax, NS, Canada
Le Boeuf, Fabrice
Autor Le Boeuf, Fabrice Cancer Therapeutics, Ottawa Hospital Research Institute, Ottawa, ON, Canada Department of Biochemistry, Microbiology and Immunology, University of Ottawa, Ottawa, ON, Canada
Clements, Derek R
Autor Clements, Derek R Department of Pathology, Dalhousie University, Halifax, NS, Canada
Fahrner, Jean-Eudes
Autor Fahrner, Jean-Eudes ORCID Gustave Roussy Comprehensive Cancer Institute, Villejuif, France INSERM, Villejuif, France Transgene S.A., Illkirch-Graffenstaden, France
Fend, Laetitia
Autor Fend, Laetitia Transgene S.A., Illkirch-Graffenstaden, France
Bell, John C
Autor Bell, John C Cancer Therapeutics, Ottawa Hospital Research Institute, Ottawa, ON, Canada Department of Biochemistry, Microbiology and Immunology, University of Ottawa, Ottawa, ON, Canada
Mossman, Karen L
Autor Mossman, Karen L McMaster Immunology Research Centre, McMaster University, Hamilton, ON, Canada Institute for Infectious Disease Research, McMaster University, Hamilton, ON, Canada Department of Pathology and Molecular Medicine, McMaster University, Hamilton, ON, Canada

Oncoimmunology. 2018 ; 7 (12) : e1503032. [epub] 20180827

ISSN 2162-4011
Zdroj

Oncolytic viruses selectively target and kill cancer cells in an immunogenic fashion, thus supporting the establishment of therapeutically relevant tumor-specific immune responses. In 2015, the US Food and Drug Administration (FDA) approved the oncolytic herpes simplex virus T-VEC for use in advanced melanoma patients. Since then, a plethora of trials has been initiated to assess the safety and efficacy of multiple oncolytic viruses in patients affected with various malignancies. Here, we summarize recent preclinical and clinical progress in the field of oncolytic virotherapy.

Klíčová slova
CAVATAK, DNX-2401, HF10, MV-NIS, Maraba MG1, Pexa-Vec, REOLYSIN, T-VEC,
Publikační typ
časopisecké články MeSH
práce podpořená grantem MeSH
přehledy MeSH

* Zobrazit nápovědu

Upřesnit dle MeSH